Dimensional Fund Advisors LP Lowers Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Dimensional Fund Advisors LP reduced its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 35.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 131,314 shares of the company's stock after selling 71,627 shares during the quarter. Dimensional Fund Advisors LP's holdings in Roivant Sciences were worth $1,553,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its holdings in Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in shares of Roivant Sciences during the 4th quarter worth $39,000. PNC Financial Services Group Inc. boosted its position in Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock valued at $84,000 after purchasing an additional 1,507 shares in the last quarter. Wells Fargo & Company MN boosted its position in Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after purchasing an additional 3,426 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in Roivant Sciences by 550.1% in the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company's stock valued at $91,000 after purchasing an additional 6,667 shares during the last quarter. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 21st.

Roivant Sciences Stock Down 1.2%

ROIV stock opened at $10.91 on Thursday. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The stock has a market capitalization of $7.78 billion, a PE ratio of -72.73 and a beta of 1.23. The firm has a 50 day moving average of $10.53 and a 200 day moving average of $11.07.

Insider Activity

In other Roivant Sciences news, major shareholder Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $11.47, for a total transaction of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares in the company, valued at approximately $456,501,538.17. The trade was a 0.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the firm's stock in a transaction on Monday, April 21st. The stock was sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the transaction, the chief operating officer now directly owns 1,116,345 shares of the company's stock, valued at approximately $11,409,045.90. This trade represents a 8.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,123,959 shares of company stock valued at $12,355,035 over the last ninety days. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.